Ver.1.0

Info Sheet for Technical description

No. 0017

Organization

* Mandatoty fields

Name of Organization*	Cyto-Facto Inc.	
Address, City, States, Zip, Country*	Shimin Byoin Mae Bldg 3F, 2-1-11 Minatojima-minamimachi, Chuo-ku, Kobe, 650-0047, Japan.	
URL	https://www.cytofacto.com/en/	
Brief Descriptions of Organization* (Approx. 100 words)	We provide comprehensive, high-quality services from R&D to process development in compliance with GMP and GCTP, clinical trial production, and commercial production. We also provide QC testing services under GMP management, analytical validation, compliance with reliability assurance standards, and product-specific characteristic analysis testing for customers. Our newly developed cloud-based cell manufacturing management system, CytoFactory 4.0™, resolves various issues faced in the manufacturing of gene and cell preparations. In addition to the entire manufacturing process from raw material acceptance, cell processing, quality testing, and shipping, it is possible to collect and store all	
Contact address	Name*	Yoshitaka Tamai, Ph.D
	Department* / Position	Head of Business Development
	E-mail* / TEL	tamai.yoshitaka@cytofacto.com / +81-78-306-2067

What kind of technology do you want to offer? *

- ☐ **A.** Clinical Development Pipelines → Please see **Sheet【A】**
- ☑ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Servicies etc. → Please see **Sheet【B】**
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet【C】**

  * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☑ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☑ Yes
- ☐ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☑ Series A
- ☐ Series B
- ☐ Series C
- ☐ Series D or further advenced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☑ Yes	We are seeking for potential customers of CDMO services in gene/cell therapy.
☐ No	

cell

Filled in by*	Yoshitaka Tamai, Ph.D
Date*	9 September, 2024

Ver.1.0

Sheet【B】 Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Servicies etc.

Info Sheet for Technical overview

No. 0017

* Mandatoty fields

Title*

CDMO Servicies,

Category*

☐	Facilities	☐	Manufacturing equipment	☐	Inspection equipment
☐	Cells	☐	Culture medium	☐	Reagents
☐	Cell banking	☐	Storage / Container	☐	Logistics
☐	Cell / Viral vector manufacturing technology				

Description*

We provide comprehensive, high-quality services from R&D to process development in compliance with GMP and GCTP, clinical trial production, and commercial production. We also provide QC testing services under GMP management, analytical validation, compliance with reliability assurance standards, and product-specific characteristic analysis testing for customers.
Our newly developed cloud-based cell manufacturing management system, CytoFactory 4.0™, resolves various issues faced in the manufacturing of gene and cell preparations. In addition to the entire manufacturing process from raw material acceptance, cell processing, quality testing, and shipping, it is possible to collect and store all kinds of information, such as inventory, facility, and equipment status management.

Filled in by*	Yoshitaka Tamai, Ph.D
Date*	9 September, 2024